BANK VONTOBEL/CALL/NOVO NORDISK ADR B/115/0.1/20.09.24

BANK VONTOBEL/CALL/NOVO NORDISK ADR B/115/0.1/20.09.24 Stock

DE000VM31AB9

Market Closed - Deutsche Boerse AG 01:47:58 2024-07-12 pm EDT
2.69 ^EUR	+12.08%

Current month	-5.94%
1 month	-5.28%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart NOVO NORDISK A/S

Chart BANK VONTOBEL/CALL/NOVO NORDISK ADR B/115/0.1/20.09.24

Latest news about NOVO NORDISK A/S

Thinking about trading options or stock in Tesla, Microsoft, Novo Nordisk, Intel, or Solaredge Technologies?	Feb. 07	PR
Thinking about buying stock in NKGen Biotech, Novo Nordisk, SoundHound AI, Safety Shot, or Energy Fuels?	Feb. 01	PR
Thinking about buying stock in Estrella Immunopharma, Novo Nordisk, C4 Therapeutics, Plug Power, or LQR House?	Jan. 17	PR
Thinking about buying stock in Transphorm Technology, Stronghold Digital Mining, Broadcom, Novo Nordisk, or Datadog?	Jan. 11	PR

More news

Quotes 5-day view

Date	Price	Change
24-07-12	2.69	+12.08%
24-07-11	2.4	-10.45%
24-07-10	2.68	+3.88%
24-07-09	2.58	-7.19%
24-07-08	2.78	+2.96%

Delayed Quote Deutsche Boerse AG

Last update July 12, 2024 at 01:47 pm EDT

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	NOVO NORDISK A/S
Issuer	Vontobel
WKN	VM31AB
ISIN	DE000VM31AB9
Date issued	2023-10-16
Strike	115 $
Maturity	2024-09-20 (69 Days)
Parity	10 : 1
Emission price	1.03 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	3.21 €
Lowest since issue	0.49 €
Delta	0.93x
Omega	4.565
Premium	1.33x
Gearing	4.91x
Moneyness	1.235
Difference Strike	-27.07 $
Difference Strike %	-23.54%
Spread	0.01 €
Spread %	0.38%
Intrinsic value	2.483

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

More about the company

Ratings for Novo Nordisk A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Novo Nordisk A/S

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

980.3 DKK

Average target price

956.5 DKK

Spread / Average Target

-2.43%

Consensus